The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-29 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Erythropoietin (; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted in sufficient quantities to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease. Erythropoietin is largely synthesized in the deep renal cortex by peritubular interstitial fibroblast-like cells, namely located primarily in close association with the peritubular capillaries and proximal convoluted tubule; it is also produced in perisinusoidal cells in the liver. Liver production predominates in the fetal and perinatal period; renal production predominates in adulthood. It is homologous with thrombopoietin. Exogenous erythropoietin, recombinant human erythropoietin (rhEPO), is produced by recombinant DNA technology in cell culture and are collectively called erythropoiesis-stimulating agents (ESA): two examples are epoetin alfa and epoetin beta. ESAs are used in the treatment of anemia in chronic kidney disease, anemia in myelodysplasia, and in anemia from cancer chemotherapy. Risks of therapy include death, myocardial infarction, stroke, venous thromboembolism, and tumor recurrence. Risk increases when EPO treatment raises hemoglobin levels over 11 g/dL to 12 g/dL: this is to be avoided.
No well-accepted theory explains the significance of circumcision to the Egyptians, but it appears to have been endowed with great honor and importance as a rite of passage, performed in a public ceremony emphasizing the continuation of family generations and fertility. It may have been a mark of distinction for the elite: the Egyptian Book of the Dead describes the sun god Ra as having circumcised himself.
The dinoflagellates are yet another very large and diverse group, around half of which are at least partially photosynthetic (i.e. mixotrophic). Dinoflagellate chloroplasts have relatively complex history. Most dinoflagellate chloroplasts are secondary red algal derived chloroplasts. Many dinoflagellates have lost the chloroplast (becoming nonphotosynthetic), some of these have replaced it though tertiary endosymbiosis. Others replaced their original chloroplast with a green algal derived chloroplast. The peridinin chloroplast is thought to be the dinophytes' "original" chloroplast, which has been lost, reduced, replaced, or has company in several other dinophyte lineages. The most common dinophyte chloroplast is the peridinin-type chloroplast, characterized by the carotenoid pigment peridinin in their chloroplasts, along with chlorophyll a and chlorophyll c2. Peridinin is not found in any other group of chloroplasts. The peridinin chloroplast is bounded by three membranes (occasionally two), having lost the red algal endosymbiont's original cell membrane. The outermost membrane is not connected to the endoplasmic reticulum. They contain a pyrenoid, and have triplet-stacked thylakoids. Starch is found outside the chloroplast. Peridinin chloroplasts also have DNA that is highly reduced and fragmented into many small circles. Most of the genome has migrated to the nucleus, and only critical photosynthesis-related genes remain in the chloroplast.
In 18th-century Europe, it is estimated that 400,000 people died from the disease per year, and that one-third of all cases of blindness were due to smallpox. Smallpox is estimated to have killed up to 300 million people in the 20th century and around 500 million people in the last 100 years of its existence. Earlier deaths included multiple European monarchs. As recently as 1967, 15 million cases occurred a year. Inoculation for smallpox appears to have started in China around the 1500s. Europe adopted this practice from Asia in the first half of the 18th century. In 1796, Edward Jenner introduced the modern smallpox vaccine. In 1967, the World Health Organization intensified efforts to eliminate the disease. Smallpox is one of two infectious diseases to have been eradicated, the other being rinderpest (a disease of even-toed ungulates) in 2011. The term "smallpox" was first used in England in the 16th century to distinguish the disease from syphilis, which was then known as the "great pox". Other historical names for the disease include pox, speckled monster, and red plague.
Sources: en.wikipedia.org
== Single-cell protein and gasohol projects == Even greater expectations of biotechnology were raised during the 1960s by a process that grew single-cell protein. When the so-called protein gap threatened world hunger, producing food locally by growing it from waste seemed to offer a solution. It was the possibilities of growing microorganisms on oil that captured the imagination of scientists, policy makers, and commerce. Major companies such as BP staked their futures on it. In 1962, BP built a pilot plant at Cap de Lavera in Southern France to publicize its product, Toprina. Initial research work at Lavera was done by Alfred Champagnat, In 1963, construction started on BP's second pilot plant at the Grangemouth Refinery in Scotland. As there was no well-accepted term to describe the new foods, in 1966 the term "single-cell protein" (SCP) was coined at MIT to provide an acceptable and exciting new title, avoiding the unpleasant connotations of microbial or bacterial. The "food from oil" idea became quite popular by the 1970s, when facilities for growing yeast fed by n-paraffins were built in a number of countries. The Soviets were particularly enthusiastic, opening large "BVK" (belkovo-vitaminny kontsentrat, i.e., "protein-vitamin concentrate") plants next to their oil refineries in Kstovo (1973) and Kirishi (1974). By the late 1970s, however, the cultural climate had completely changed, as the growth in SCP interest had taken place against a shifting economic and cultural scene (136).
Sub-slab depressurization (soil suction) by increasing under-floor ventilation; Improving the ventilation of the house and avoiding the transport of radon from the basement into living rooms; Installing a radon sump system in the basement; Installing a positive pressurization or positive supply ventilation system. According to the EPA, the method to reduce radon "...primarily used is a vent pipe system and fan, which pulls radon from beneath the house and vents it to the outside", which is also called sub-slab depressurization, active soil depressurization, or soil suction. Generally indoor radon can be mitigated by sub-slab depressurization and exhausting such radon-laden air to the outdoors, away from windows and other building openings. "[The] EPA generally recommends methods which prevent the entry of radon. Soil suction, for example, prevents radon from entering your home by drawing the radon from below the home and venting it through a pipe, or pipes, to the air above the home where it is quickly diluted" and the "EPA does not recommend the use of sealing alone to reduce radon because, by itself, sealing has not been shown to lower radon levels significantly or consistently". Positive-pressure ventilation systems can be combined with a heat exchanger to recover energy in the process of exchanging air with the outside, and simply exhausting basement air to the outside is not necessarily a viable solution as this can actually draw radon gas into a dwelling.
Many cell signals are carried by molecules that are released by one cell and move to make contact with another cell. Signaling molecules can belong to several chemical classes: lipids, phospholipids, amino acids, monoamines, proteins, glycoproteins, or gases. Signaling molecules binding surface receptors are generally large and hydrophilic (e.g. TRH, Vasopressin, Acetylcholine), while those entering the cell are generally small and hydrophobic (e.g. glucocorticoids, thyroid hormones, cholecalciferol, retinoic acid), but important exceptions to both are numerous, and the same molecule can act both via surface receptors or in an intracrine manner to different effects. In animal cells, specialized endocrine cells release these hormones and send them through the circulatory system to other parts of the body. They then reach target cells, which can recognize and respond to the hormones and produce a result. This is also known as endocrine signaling. Plant growth regulators, or plant hormones, move through cells or by diffusing through the air as a gas to reach their targets. Hydrogen sulfide is produced in small amounts by some cells of the human body and has a number of biological signaling functions. Only two other such gases are currently known to act as signaling molecules in the human body: nitric oxide and carbon monoxide.
In 1965, with at least 500 shareholders and on the cusp of bankruptcy, National Semiconductor went "marginally" publicly traded through Pink Sheets at a starting price of $3. Alan Lopato was the market maker with a list of significant shareholders. Due to Rothlein's lack of belief in integrated circuits, and before Sporck was hired, Jack Hegarty replaced Dr Rothlein as CEO, and Don Lucas became chairman, immediately followed by Peter Sprague becoming chairman. In 1966, Sprague hired five top executives away from Fairchild, among whom were Charles E. Sporck, Pierre Lamond, Don Valentine, Floyd Kvamme. At the time of Sporck's hiring, Robert Noyce was de facto head of semiconductor operations at Fairchild and Sporck was his operations manager. Sporck was appointed president and CEO of National. To make the deal better for Sporck's hiring and appointment at half his former salary at Fairchild, Sporck was allotted a substantial share of National's stock. Sporck also brought over three other people from TI, Perkin-Elmer, and Hewlett-Packard to form a new eight-man team at National Semiconductor. The group was allotted 9.6% of the company's stock and after the deal was announced, the stock soared from $3-$4 to $24. Sporck had been Widlar's superior at Fairchild before Widlar left Fairchild to join Molectro after a compensation dispute with Sporck. In 1968, National shifted its headquarters from Danbury, Connecticut, to Santa Clara, California. However, like many companies, National retained its registration as a Delaware corporation, for legal and financial expediency.
Many soluble salts of acid dyes synthesized for textile-related purposes were transformed into insoluble salts or lake pigments by reaction with water-soluble salts of calcium, barium or lead, whereas basic dyes were treated with tannins or antimony potassium tartrate to yield pigments.
Sources: en.wikipedia.org
Bloch's was a philosophy that could hold its head high before the most advanced literature; a philosophy that was not calibrated to the abominable resignation of methodology ... I took this motif so much as my own that I do not believe I have ever written anything without reference to it, either implicit or explicit.Adorno's intellectual non-conformism was also shaped by the repugnance he felt towards the nationalism that swept through the Reich during the First World War. Along with future collaborators Walter Benjamin, Max Horkheimer, and Ernst Bloch, Adorno was profoundly disillusioned by the ease with which Germany's intellectual and spiritual leaders—among them Max Weber, Max Scheler and Georg Simmel, as well as his friend Siegfried Kracauer—came out in support of the war. The younger generation's distrust for traditional knowledge arose from how this tradition had discredited itself. Over time, Oscar Wiesengrund's firm established close professional and personal ties with the factory of Karplus & Herzberger in Berlin. The eldest daughter of the Karplus family, Margarete, or Gretel, moved into the intellectual circles of Berlin, where she became acquainted with Benjamin, Bertolt Brecht, and Bloch, each of whom Adorno would become familiar with during the mid-1920s. After fourteen years, Gretel Karplus and Adorno were married in 1937.
Protein sequence and structure are important additional classification criteria for the three superfamilies (cytosolic, mitochondrial, and MAPEG) of GSTs: while classes from the cytosolic superfamily of GSTs possess more than 40% sequence homology, those from other classes may have less than 25%. Cytosolic GSTs are divided into 13 classes based upon their structure: alpha, beta, delta, epsilon, zeta, theta, mu, nu, pi, sigma, tau, phi, and omega. Mitochondrial GSTs are in class kappa. The MAPEG superfamily of microsomal GSTs consists of subgroups designated I-IV, between which amino acid sequences share less than 20% identity. Human cytosolic GSTs belong to the alpha, zeta, theta, mu, pi, sigma, and omega classes, while six isozymes belonging to classes I, II, and IV of the MAPEG superfamily are known to exist.
==== MeSH E05.200.500 – cytological techniques ==== MeSH E05.200.500.105 – autoradiography MeSH E05.200.500.195 – cell count MeSH E05.200.500.195.107 – blood cell count MeSH E05.200.500.195.107.330 – erythrocyte count MeSH E05.200.500.195.107.330.725 – reticulocyte count MeSH E05.200.500.195.107.595 – leukocyte count MeSH E05.200.500.195.107.595.500 – lymphocyte count MeSH E05.200.500.195.107.595.500.150 – cd4 lymphocyte count MeSH E05.200.500.195.107.595.500.150.160 – cd4-cd8 ratio MeSH E05.200.500.195.107.740 – platelet count MeSH E05.200.500.195.870 – sperm count MeSH E05.200.500.251 – cell fractionation MeSH E05.200.500.307 – cell fusion MeSH E05.200.500.363 – cell separation MeSH E05.200.500.363.285 – cytapheresis MeSH E05.200.500.363.285.570 – leukapheresis MeSH E05.200.500.363.285.790 – plateletpheresis MeSH E05.200.500.363.400 – immunomagnetic separation MeSH E05.200.500.363.540 – leukocyte reduction procedures MeSH E05.200.500.383 – colony-forming units assay MeSH E05.200.500.383.910 – tumor stem cell assay MeSH E05.200.500.385 – cytogenetic analysis MeSH E05.200.500.385.130 – chromosome banding MeSH E05.200.500.385.500 – mitotic index MeSH E05.200.500.386 – cytophotometry MeSH E05.200.500.386.350 – flow cytometry MeSH E05.200.500.386.400 – image cytometry MeSH E05.200.500.386.400.500 – laser scanning cytometry MeSH E05.200.500.387 – diffusion chambers, culture MeSH E05.200.500.388 – drug screening assays, antitumor MeSH E05.200.500.388.930 – tumor stem cell assay MeSH E05.200.500.410 – electroporation MeSH E05.200.500.607 – histocytochemistry MeSH E05.200.500.607.512 – immunohistochemistry MeSH E05.200.500.607.790 – periodic acid-schiff reaction MeSH E05.200.500.607.810 – prussian blue reaction MeSH E05.200.500.620 – histocytological preparation techniques MeSH E05.200.500.620.530 – microtomy MeSH E05.200.500.620.530.160 – cryoultramicrotomy MeSH E05.200.500.620.530.160.260 – frozen sections MeSH E05.200.500.620.620 – replica techniques MeSH E05.200.500.620.620.150 – corrosion casting MeSH E05.200.500.620.620.260 – freeze fracturing MeSH E05.200.500.620.620.260.400 – freeze etching MeSH E05.200.500.620.670 – staining and labeling MeSH E05.200.500.620.670.130 – chromosome banding MeSH E05.200.500.620.670.325 – in situ hybridization MeSH E05.200.500.620.670.325.350 – in situ hybridization, fluorescence MeSH E05.200.500.620.670.325.350.125 – chromosome painting MeSH E05.200.500.620.670.325.680 – primed in situ labeling MeSH E05.200.500.620.670.520 – negative staining MeSH E05.200.500.620.670.620 – periodic acid-schiff reaction MeSH E05.200.500.620.670.660 – prussian blue reaction MeSH E05.200.500.620.670.770 – shadowing (histology) MeSH E05.200.500.620.670.780 – silver staining MeSH E05.200.500.620.720 – tissue embedding MeSH E05.200.500.620.720.610 – paraffin embedding MeSH E05.200.500.620.720.640 – plastic embedding MeSH E05.200.500.620.760 – tissue preservation MeSH E05.200.500.620.760.160 – cryopreservation MeSH E05.200.500.620.760.160.260 – freeze drying MeSH E05.200.500.620.760.160.260.270 – freeze substitution MeSH E05.200.500.620.760.720 – tissue fixation MeSH E05.200.500.695 – karyometry MeSH E05.200.500.800 – patch-clamp techniques
==== Alkylation ==== The most common method for alkylation of the lactam nitrogen of 2,5-diketopiperazines is based on the use of sodium hydride as base. However epimerisation can occur especially with proline-fused 2,5-diketopiperazines, even with milder methods such as under phase-transfer catalyst conditions for example 1 to 2.
== Side effects == Since SNRIs and SSRIs act in similar ways to elevate serotonin levels, they share many side effects, though to varying degrees. Some common side effects include nausea, dry mouth, dizziness, sweating, increased blood pressure, loss of appetite, headache, increase in suicidal thoughts, and sexual dysfunction. Elevation of norepinephrine levels can sometimes cause anxiety, mildly elevated pulse, and elevated blood pressure. However, norepinephrine-selective antidepressants, such as reboxetine and desipramine, have successfully treated anxiety disorders. People at risk for hypertension and heart disease should monitor their blood pressure.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.